Introduction
Clinically, premature ovarian failure (POF, MIM311360) is described as an unexplained amenorrhoea (>6 months) with elevated levels of gonadotrophins (FSH >40 IU/l) before the age of 40 years. It occurs in ∼1% women. Various comprehensive studies have been reported at the chromosomal as well as the gene level to elucidate the aetiology of ovarian failure, but it still remains elusive (Schlessinger et al., 2002) . Extensive germline studies have revealed very few mutations in the gonadotrophins and their corresponding receptors except noteworthy missense variant p.Ala189Val in the extracellular domain of the FSH receptor (FSHR) gene. This variant was strongly associated with ovarian failure in the Finnish population (Aittomaki et al., 1995) . This variant is rare in other world populations. The truncated variants of the FOXL2 gene were associated with familial Type 1 blepharophimosis-ptosis-epicanthus inversus syndrome (BPES) cases where females inherit ovarian failure (Crisponi et al., 2001) . Several FOXL2 gene mutations have been reported in the Type 1 BPES and non-syndromic POF cases but are uncommon in diverse populations (De Baere et al., 2005) . The first germline study of the inhibin alpha (INHa) gene revealed a distinct missense mutation c.769G>A (p.Ala253Thr) in its mature peptide region (Shelling et al., 2000) . Various population studies including the Indian population corroborated the significant presence of this mutation in ovarian failure cases with almost absence in the controls (Shelling et al., 2000; Marozzi et al., 2002; Dixit et al., 2004) . Substantial significance of this mutation as a genetic marker for ovarian failure strongly urges germline studies of other key molecules networked around inhibin functions.
Inhibins are the most important factors directly involved in the down-regulation of FSH by a negative feedback mechanism. Failure to modulate FSH levels results in a diminished ovarian reserve and clinically characterized as hypergonadotrophic hypogonadism or POF (Welt et al., 2005) . The regulation of FSH levels is maintained by opposing actions of both inhibins and activins. These growth factors are mainly produced by granulosa cells in the ovary. These factors feedback on the FSH-producing gonadotrophs in the anterior pituitary. The activins bind their Type II receptors (ActRIIA and ActRIIB) located on the gonadotroph cell surface. The activin/ActRII complex further recruits Type I receptor ALK4. This activin/ ActRII/ALK4 complex in turn activates Smad2/3 signalling and results in an elevated production of FSH. Conversely, inhibins bind to a Type III receptor betaglycan located on the gonadotrophs. This inhibin/betaglycan complex has an equal binding affinity for activin Type II receptors and therefore competes with activin-mediated signalling. Unlike activin/ ActRII complex, the inhibin/betaglycan/ActRII complex fails to recruit ALK4 because of the lack of kinase activity in the cytoplasmic domain of betaglycan. This inhibin-mediated phenomenon is incompetent to initiate Smad signalling resulting in the down-regulation of FSH production (Lewis et al., 2000) .
The betaglycan receptor is a 300-kDa protein, which is expressed in a variety of tissues including reproductive and pituitary tissues. The expression of betaglycan mRNA and receptor in gonadotrophs fluctuates sharply with menstruation cycle stages, inhibin, FSH and estradiol (E 2 ) levels (Chapman and Woodruff, 2003) . Recent reports on the betaglycan receptor could successfully solve the mystery of inhibin action mechanism (Phillips and Woodruff, 2004) . Germline mutations in the betaglycan gene (TGFBR3) may result in its altered mRNA expression, structure and binding affinity. These alterations would be anticipated to lead to the loss of inhibin-mediated FSH down-regulation. This study has been designed to uncover germline status of the TGFBR3 gene in the cases of ovarian failure. Standard experiments were designed to obtain DNA sequencing data of all the exons. In sillico sequence analysis and various statistical parameters were designed to establish the germline status.
Materials and methods

Patient and control recruitment
One hundred and ninety-six patients with ovarian failure were recruited, which included non-familial POF cases (n = 121), familial POF cases (n = 12), non-familial PA cases (n = 56) and familial PA cases (n = 7). These patients were recruited at the Infertility Institute and Research Centre (IIRC), Hyderabad, and the Institute of Reproductive Medicine (IRM), Kolkata. Patients disclaiming any familial history of ovarian failure were categorized as non-familial/sporadic cases. Patients with the family history of ovarian failure in the same generation or parental generation were considered as familial cases. The diagnostic criteria for POF following the definition include at least 6 months of amenorrhoea before the age of 40 years, with high serum FSH levels (>40 IU/l). The criterion for PA is defined as a condition with complete absence of menses or only induced menses. All the patients were assessed clinically, with complete medical and gynaecological history, including the history of menses, age at menopause, serum FSH levels (three times at 1-month interval), LH levels, TSH levels, and with no history of any autoimmune disease. Respective consent forms from these patients were collected by the concerned clinic. Karyotyping with a high-resolution GTG banding was carried out for all the patients and controls for chromosomal anomalies. Patients and controls with chromosomal abnormalities were excluded from the study. Normal healthy females with regular menstrual history, normal FSH levels and successful pregnancies were recruited as controls (n = 200). Recruitment of the controls was entirely population-based to support the study. The Institutional Review Board of Centre for Cellular and Molecular Biology (CCMB), Hyderabad, approved the study.
DNA extraction and karyotyping
A 5-ml aliquot of peripheral blood was collected in EDTA vacutainers for genomic DNA isolation, and another 5 ml of peripheral blood was collected in heparin vacutainers for chromosomal analysis. DNA was extracted using the Nucleon BACC2 DNA extraction kit (Amersham Pharmacia Biotech, Piscataway, NJ, USA) according to the manufacturer's protocol. Chromosomal analysis was performed on phytohaemagglutinin (PHA)-stimulated peripheral lymphocyte cultures using standard conventional cytogenetic methods.
PCR
The TGFBR3 gene is comprised of 16 exons. Primers for all the exons were designed using online Genefisher software (http://bibiserv.techfak. uni-bielefeld.de/genefisher). All the PCR conditions included initial denaturation at 94°C for 5 min, cyclic denaturation at 94°C for 45 s and extension at 72°C for 1 min with total 35 cycles. All the primer sequences, with their corresponding annealing temperatures, are summarized in Table I . The presence of all sequence variants was confirmed by performing three independent PCR reactions and subsequent DNA sequencing.
DNA sequencing and analysis
All the PCR products were obtained using the above-mentioned primers, amplifying the corresponding exon and flanking regions of the gene. Sequencing was performed using the Big Dye terminator sequencing protocol, supported by Applied Biosystems using an ABI prism 3730xl DNA analyzer. The obtained sequence data were analysed using sequence analysis and autoassembler software in MacOS. The reference TGFBR3 sequence was downloaded from Ensembl database (www.ensembl.org/Homo_sapiens/index.html). The Human Genome Variation Society (HGVS) guidelines were followed for all the variant nomenclature and genotype representation throughout the text and tables.
Statistical analysis of results
SNPAlyzer
TM 5.0 software was used for performing the Hardy-Weinberg disequilibrium, Fisher's exact test, odds ratio, confidence intervals and chi-square test. Online ISTECH SNPAnalyzer software was used for haplotyping. Multinomial logistic regression analysis was performed using SPSS 11.0 software.
Results
The sequencing data collection and analysis was successfully performed for the coding regions of TGFBR3 gene in all the cases and controls, which included non-familial POF cases (n = 121), familial POF cases (n = 12), non-familial PA cases (n = 56), familial PA cases (n = 7) and controls (n = 200). The patients as well as the control populations were in HardyWeinberg equilibrium for all the genetic variations. The post hoc power analysis confirmed the good strength of patient and control populations for this study. In the POF cases, the mean age of attaining amenorrhoea was 26 years (range 14-40 years), mean FSH level was 59.3 IU/l and mean LH level was 33.7 IU/l. Women with regular menstrual cycles, successful pregnancies and normal FSH levels (4-11 IU/l) were recruited as controls (age range 30-45 years). The control group mean FSH level was 7.3 IU/l and mean age 37 years.
This study revealed 46 sequence variants including 22 novel variants. All the sequence variants were confirmed by the repetition of three independent PCR and sequencing reactions, including sequencing in the reverse direction also. The novel variants include six exonic variants and 16 intronic variants. The details of all the variants have been summarized in Table II . Two novel coding variants were missense, i.e. c.550 A>G (p.Iso184Val) in a control and c.2323C>T (p.Pro775Ser) in a POF case. On the basis of Fisher's exact test, allelic frequencies for three variants were almost significantly diverse in cases of ovarian failure than in controls as given below: (i) c.382-81C>T (P = 0.0136 for POF and P = 0.0606 for PA), (ii) c.382-77T>C (P = 0.0136 for POF, P = 0.0606 for PA) and (iii) c.1200G>A (P = 0.0669 for POF and P = 0.0875 for PA). The genotypic distribution for these three variants was also significantly varied (95% confidence level) in patients as compared with controls as summarized in Table III . Notably, the C allele of c.382-81C>T variant was always linked with the C allele of c.382-77T>C and vice versa. Unconditional multinomial logistic regression analysis was performed for the c.382-81C>T variant and c.1200G>A variant to estimate the relative risk for ovarian failure. These variants were chosen for regression analysis considering significant genotypic differences in the patients as compared with the controls at 95% confidence limits. The c.382-77T>C variant was not chosen for regression analysis because of its complete linkage with the c.382-81C>T variant. The multinomial regression model was significant for both the patient populations (P < 0.00005 for POF and P = 0.007 for PA) as compared with the controls with a pseudo-R 2 value (Nagelkerke) of 0.04. Both the genotypes showed almost significant regression P values as summarized in Table IV . On the basis of high frequency of minor allele (>5%) and the significant differences in genotype distribution at 80% confidence level (P < 0.2), five variants, namely c.382-81C>T, c.382-77T>C, c.566-216G>A, c.1200G>A and c.2022T>C, were chosen for haplotyping. The criterion for using 80% confidence limit was not to represent the association status of individual variants but rather to restrict variants for their cumulative effects. The variants other than these five were either rare or showed almost similar genotypic distribution among the patients and the controls. The details of these five variants with varied genotypic distribution in either POF cases or PA cases as compared with the controls are summarized in Table III . The significance of the haplotype analysis was represented following the Bonferroni's correction guidelines. The CCAAT haplotype was significantly higher in the patients as compared with the controls (P = 0.00007). The TTAGT haplotype was significantly higher in the controls than in patients (P = 0.001). Other less frequent haplotypes like CCGAC and TTAAT were only present in the patients (P = 0.0096 and 0.0003, respectively). The details of all haplotyping analysis are summarized in Table V .
Discussion
POF is largely considered a heterogeneous genetic disorder. The elevation of serum FSH levels is a prominent clinical feature of POF. Normal cyclic pulses of the serum FSH levels are regulated by opposing actions of activins and inhibins. This antagonistic activity of inhibins against activins was first (Martens et al., 1997) . The direct binding affinity of inhibins to the activin Type II receptor is ∼10-fold lower than the activin-binding affinity for this receptor. Conversely, in vivo equimolar or even lower serum inhibin concentrations are able to antagonize activin activity with equal strength, suggesting the presence of a separate inhibin receptor (Lewis et al., 2000) . Lewis et al. (2000) reported betaglycan as a first inhibinspecific receptor that satisfies all the receptor criteria. This receptor binds inhibins with high affinity. This inhibin/betaglycan complex is equally capable of competing with activin for its binding with Type II activin receptor. This complex of inhibin/betaglycan/ActRII is unable to recruit Type I receptor ALK4 and subsequently FSH secretion (Lewis et al., 2000) . In situ hybridization analyses of rat tissues confirmed localized expression of the betaglycan mRNA and protein in anterior and intermediate lobes of pituitary, oocytes, granulosa cells and theca cells. The inhibin target cells, i.e. gonadotrophs, showed 97% immunoreactivity for betaglycan co-expression (MacConell et al., 2002) . The co-localization studies of FSHb and betaglycan in the gonadotrophs illustrated an increased expression of betaglycan with high serum inhibin levels while being inversely correlated with serum FSH levels. In the ovary, primary follicles presented light hybridization signal for the betaglycan, whereas more moderate levels were seen in follicular granulosa, thecal cells as well as the oocytes. The ovarian interstitial cells present high levels of signal for the betaglycan (Chapman and Woodruff, 2003) . The regulatory effect of FSH and E 2 on the betaglycan mRNA transcript was evaluated in cultured rat granulosa cells. Both FSH and E 2 synergistically up-regulate its transcript levels by increasing mRNA stability (Omori et al., 2005) . These results suggest that apart from FSH regulation in the gonadotrophs, betaglycan may also have a locally important role in ovarian follicle proliferation and oocyte maturation, but further research is required to elucidate such a role. The earliest mutation study of the TGFBR3 (betaglycan) gene reported 12 variants including one triple-nucleotide insertion (Zippert et al., 2000) . This study was performed using mRNA and genomic DNA isolated from six healthy Caucasian individuals and 20 healthy Caucasian individuals, respectively. This study provides the first case-control study to investigate the role of TGFBR3 gene in genetic aetiology of ovarian failure. The mutational analysis was performed for the TGFBR3 gene-coding regions and respective flanking intronic regions that were PCR amplified in cases of ovarian failure and controls (details in Materials and methods). This study revealed 46 sequence variants including 22 novel variants. These novel variants included six exonic variants and 16 intronic variants. Of all the variants revealed in this study, only two variants c.1200G>A and c.2022T>C were similar to previously published variants by Zippert et al. (2000) . Other reported variants were documented in the SNP database during genome sequencing projects. Two novel exonic variants were missense as follows: (i) c.550A>G (p.Iso184Val) in a control and (ii) c.2323C>T (p.Pro775Ser) in a POF case. The missense variant c.550A>G was non-conserved among all present available vertebrates sequences but seems to lack an apparent functional effect because of the substitution by the same group amino acid. The wild-type c.2323C (also p.775Pro) was found to be conserved among the present available primate sequences but not to other vertebrate sequences. This mutation results in the substitution of an imino proline to hydroxyl group containing serine which may cause some functional defects in the protein activity. The patient harbouring c.2323C>T variant was genotypically heterozygous with FSH (82 IU/l), LH (43 IU/l) and TSH (2.6 mIU/l) hormone levels. Two variants represented significantly diverse genotypic distribution (95% confidence level) particularly in POF cases but not in PA cases than in controls as detailed: (i) c.382-81C>T (P = 0.0170 for POF and P = 0.1569 for PA) and (ii) c.382-77T>C (P = 0.0170 for POF and P = 0.1569 for PA). The c.1200G>A variant represented significantly different genotype distribution in both the patient populations (POF cases and PA cases) than in the controls (P = 0.00003 for POF and P = 0.00009 for PA). Notably, the significant diversion of this variation was not obvious at 95% confidence limits with the Fisher's exact test. The logistic regression analysis of c.382-81C>T and c.1200G>A variants was significant among cases of ovarian failure (P < 0.00005 for POF and P = 0.007 for PA) with a pseudo-R 2 value (Nagelkerke) of 0.04. Both the genotypes showed almost significant regression P values as summarized in Table IV . The haplotype analysis was performed using five variants, namely c.382-81C>T, c.382-77T>C, c.566-216G>A, c.1200G>A and c.2022T>C as detailed in the Results. The Bonferroni's correction of multiple comparison was performed for haplotype analysis to set the significant P value (P < 0.0125) at 95% confidence level. The CCAAT haplotype was most significantly over-represented in the patients as compared with the controls (P = 0.00007). The TTAGT haplotype was significantly higher in the controls than in patients (P = 0.001). Other less frequent haplotypes like CCGAC and TTAAT were only present in the patients (P = 0.0096 and 0.0003 respectively).
In conclusion, this study provides the first germline casecontrol status of the TGFBR3 gene to support the aetiology of ovarian failure. This study presents a spectrum of 46 sequence variants that include six novel exonic variants and 16 novel intronic variants. So far, only two variants have been reported as a published work, whereas the remaining known variants have been documented during genome sequencing. The genotypic distributions were significantly varied for c.382-81C>T, c.382-77T>C and c.1200G>A variant, suggesting their possible importance in the genetic aetiology of ovarian failure. The haplotype analysis represented the significant association of major CCAAT haplotype with ovarian failure. In conclusion, the TGFBR3 gene may contribute to the aetiology of ovarian failure, possibly with other genetic and environmental factors.
